Article Text

other Versions

PDF
Effectiveness of an once weekly double dose of etanercept in patients with JIA: a clinical study
  1. Femke H.M. Prince (f.prince{at}erasmusmc.nl)
  1. Erasmus MC Sophia Children's Hospital, Netherlands
    1. Marinka Twilt (m.twilt{at}erasmusmc.nl)
    1. Erasmus MC Sophia Children's Hospital/ Leiden University Medical Center, Netherlands
      1. Nelleke C. J. A. Jansen-Wijngaarden (c.j.a.jansen{at}erasmusmc.nl)
      1. Erasmus MC Sophia Children's Hospital, Netherlands
        1. Lisette W.A. van Suijlekom-Smit (l.vansuijlekom{at}erasmusmc.nl)
        1. Erasmus MC Sophia Children's Hospital, Netherlands

          Abstract

          Etanercept is effective in Juvenile Idiopathic Arthritis (JIA).[1-3] Currently it is administered subcutaneously (SC) in the dose of 0,4 mg/kg (maximum of 25 mg) twice weekly. Clinical trials in adults show that the administering of an once weekly double dose is effective enough to induce and retain remission.[4, 5] A farmakinetic model developed by Yim et al. indicates that the same dosing regime could be used in children. [6] Wallace mentions the once weekly double dose in patients with JIA, but this is not supported by clinical trials.[7] Therefore we evaluated the efficacy of etanercept administered once weekly in the dose of 0,8 mg/kg SC (maximum of 50 mg) to retain and induce remission in patients with JIA.

          • Juvenile Idiopathic Arthritis
          • double dose
          • etanercept
          • once weekly

          Statistics from Altmetric.com

          Request permissions

          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.